Manuscript no. HAEMATOL/2011/041905 entitled “Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study“


Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Clara D. Bloomfield, MD, The Ohio State University Comprehensive Cancer Center, clara.bloomfield@osumc.edu
   • Guido Marcucci, MD, The Ohio State University Comprehensive Cancer Center, guido.marcucci@osumc.edu

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Heiko Becker, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Guido Marcucci, and Clara D. Bloomfield

3) Design & Methods. The following authors were responsible for specific investigations: Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Sebastian Schwind, and Yue-Zhong Wu carried out laboratory-based research. Kati Maharry, Michael D. Radmacher, and Jessica Kohlschmidt performed statistical analyses. Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Joseph O. Moore, Michael A. Caligiuri, Richard A. Larson, Guido Marcucci, and Clara D. Bloomfield were involved directly or indirectly in care of patients and/or sample procurement.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables:
   • Heiko Becker, Kati Maharry, Krzysztof Mrózek, Guido Marcucci, and Clara D. Bloomfield were responsible for the paragraphs “Frequencies and pretreatment features of the rs16754 genotypes”, “Outcome according to the rs16754 genotypes” and “Outcome comparisons of the WT1AA versus the WT1AG/WT1GG genotypes in different age groups” and for Table 1, Table 2 and Figure 1.
   • Heiko Becker, Michael D. Radmacher, Krzysztof Mrózek, Guido Marcucci, and Clara D. Bloomfield were responsible for the paragraph “Gene- and microRNA-expression profiling of the rs16754 genotypes” and Figure 2.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
6) Contributors Listed in Acknowledgments:
The Cancer and Leukemia Group B institutions, principal investigators, and cytogeneticists participating in this study are provided in the Supplementary Appendix. The authors thank Donna Bucci of the Cancer and Leukemia Group B Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services, Lisa J. Sterling and Colin G. Edwards, PhD for data management, and Deedra Nicolet for statistical analyses. This work was supported in part by National Cancer Institute, Bethesda, MD grants CA101140, CA114725, CA140158, CA31946, CA33601, CA16058, CA77658 and CA129657, The Coleman Leukemia Research Foundation and the Deutsche Krebshilfe – Dr. Mildred Scheel Cancer Foundation (Heiko Becker).